Halozyme Therapeutics, Inc. (HALO)

63.08 -1.41 (-2.19%) USD  |  NASDAQ  |  Apr 06, 16:00
63.09 +0.01 (+0.02%) After-Hours: 20:00
More

Halozyme Therapeutics SG&A Expense (TTM) : 207.09M for Dec. 31, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Skye Bioscience, Inc. 15.80M
Johnson & Johnson 23.68B
Eli Lilly & Co. 11.09B
Stryker Corp. 8.651B
Glaukos Corp. 331.75M